Preparation and Stability Evaluation of Extemporaneous Oral Suspension of Valsartan Using Commercially Available Tablets
Author(s): Zaid Abdel Naser, Assali Mohyeddin, Qaddomi Aiman, Ghanem Mashhour, Zaaror Yara Abu
Issue: Mar/Apr 2014 - Volume 18, Number 2
View All Articles in Issue
Page(s): 169-174
Download in electronic PDF format for $75
Abstract: The aim of this study was to develop an extemporaneous valsartan suspension (80 mg valsartan/ 5 mL) starting from commercial tablets (80-mg/ tablet). A high-performance liquid chromatographic system was used for the analysis and quantification of valsartan in the samples studied. Samples of valsartan suspension for analysis were prepared as reported by the validated high-performance liquid chromatographic method and the dissolution tests were performed according to the U.S. Food and Drug Administration’s method. The high-performance liquid chromatographic assay indicated that the 80-mg/5-mL valsartan suspension was stable for 30 days when stored at long-term and accelerated storage conditions. Valsartan release profile showed that approximately 85% of valsartan dissolved after 10 minutes and, accordingly, the calculation of similarity factor was not necessary. It is possible for the pharmacist to crush valsartan 80-mg tablets and prepare a suspension which has dosage flexibility that can be calculated according to body-surface area, kidney, and liver functions, without affecting the chemical stability of the active ingredient nor its dissolution profile and also have a cost-effective dosage form.
Related Keywords:
Abdel Naser Zaid, PhD, Mohyeddin Assali, Aiman Qaddomi, Mashhour Ghanem, Yara Abu Zaaror, valsartan, oral suspension, formulation, stability, Palestine
| Related Articles from IJPC |
Title/Author
(Click for Abstract / Details / Purchase) |
Issue/Page
View/Buy |
Preparation and Stability Evaluation of Extemporaneous Oral Suspension of Valsartan Using Commercially Available Tablets
Zaid Abdel Naser, Assali Mohyeddin, Qaddomi Aiman, Ghanem Mashhour, Zaaror Yara Abu
|
Mar/Apr 2014
Pg. 169-174
|
Formulation, Physical Stability, and the Clinical Effectiveness of Extemporaneous Ivermectin Oral Solution
Zaid Abdel-Naser, Zaaror Yara Abu, Qaddumi Aiman, Ratrout Ala, Ahmad Ayda, Hamad Emad, Kittana Naim
|
Nov/Dec 2021
Pg. 523-527
|
Formulation Development and Stability Testing of Extemporaneous Suspension Prepared From Dapsone Tablets
Kaila Nitin, El-Ries Mohamed, Riga A, Alexander Kenneth S, Dollimore D
|
May/Jun 2003
Pg. 233-239
|
Formulation and Accelerated Stability Studies for an Extemporaneous Suspension of Amiodarone Hydrochloride
Alexander Kenneth S, Thyangarajapuram N
|
Sep/Oct 2003
Pg. 389-393
|
Comparison of Rheological and Sedimentation Behavior of Commercially Available Suspending Vehicles for Oral Pharmaceutical Preparations
Visser J Carolina, ten Seldam Inge E J, van der Linden Isabella J, Hinrichs Wouter L J, Veenendaal Reinier F H, Dijkers Eli C F, Woerdenbag Herman J
|
May/Jun 2018
Pg. 247-251
|
Physicochemical Stability of the Extemporaneous Ibuprofen Oral Suspension in "Wagner" Base
Spennacchio Antonio, Lopedota Angela, la Forgia Flavia, Fontana Sergio, Franco Massimo, Denora Nunzio
|
Jan/Feb 2023
Pg. 72-77
|
Stability of Commercially Available Grape and Compounded Cherry Oral Vancomycin Preparations Stored in Syringes and Cups
Kirk Loren, Lewis Paul, Luu Yao, Brown Stacy
|
Mar/Apr 2016
Pg. 159-163
|
Valsartan 16-mg/mL Oral Suspension
Allen Loyd V Jr
|
May/Jun 2019
Pg. 237
|
Formulation and Stability Evaluation of Extemporaneously Prepared Atenolol Capsules from Crushed Atenolol Tablets
Zaid Abdel Naser, Malkieh Numan, Kharoaf Maher, Ghoush Abeer Abu, Al-Ramahi Rowa'
|
Jul/Aug 2012
Pg. 342-346
|
Stability of Extemporaneously Prepared Hydroxycarbamide Oral Suspensions
Kabiche Djamila, Balde Issa-Bella, Majoul Elyes, Kabiche Sofiane, Bourguignon Elodie, Fontan Jean-Eudes, Cisternino Salvatore, Schlatter Joel
|
Mar/Apr 2017
Pg. 160-163
|
Evaluation of Extemporaneous Oral Itraconazole Suspensions by Dissolution Profiles Mapping
Tong Henry H Y, Chan Hokman, Du Zhen, Zheng Ying
|
Jul/Aug 2010
Pg. 342-345
|
Physicochemical and Microbiological Stability of Extemporaneously Compounded Hydrocortisone Oral Suspensions in PCCA Base, SuspendIt
Pramar Yashoda V, Mandal Tarun K, Bostanian Levon A, Kader Cyndy, Morris Tommy C, Graves Richard A
|
Sep/Oct 2021
Pg. 431-439
|
Women's Oral Health: Is There a Hormonal Link?
Preckshot John
|
Jan/Feb 2004
Pg. 10-14
|
Stability of Extemporaneous Oral Tramadol, Fluoxetine, and Doxycycline Suspensions in SyrSpend SF pH4
Espana B, Joseph-Tornabène F, Jaquet Cécile, Perrot S, Prouillac C
|
Jul/Aug 2020
Pg. 327-336
|
Chemical Stability of Perphenazine in Two Commercially Available Vehicles for Oral Liquid Dosage Forms
Gupta Vishnu D
|
Jul/Aug 2008
Pg. 372-374
|
Physical and Chemical Stability of Budesonide Mucoadhesive Oral Suspensions (MucoLox)
Ip Kendice, Carvalho Maria, Shan Ashley, Banov Daniel
|
Jul/Aug 2017
Pg. 322-329
|
Stability of an Alcohol-free, Dye-free Hydrocortisone (2 mg/mL) Compounded Oral Suspension
Manchanda Arushi, Laracy Melissa, Savji Taslim, Bogner Robin H
|
Jan/Feb 2018
Pg. 66-75
|
Stability Issues for Compounding Extemporaneously Prepared Oral Formulations for Pediatric Patients
Schotik Debora
|
Jan/Feb 2001
Pg. 9-12
|
Stability of Allopurinol Suspension Compounded from Tablets
Alexander Kenneth S, Davar Nipun, Parker Gordon A
|
Mar/Apr 1997
Pg. 128-131
|
Valsartan 4-mg/mL in SyrSpend SF pH4
Allen Loyd V Jr
|
Jul/Aug 2021
Pg. 329
|
| Return to Top |
